Amgen pleaded guilty over Aranesp and paid $762 million. Then it kept paying.

By ··1 min read·2 sources

The 2012 plea is a criminal conviction. Further settlements followed within months and continued for years.

Amgen pleaded guilty in Brooklyn in December 2012 to introducing a misbranded drug into interstate commerce. It had promoted Aranesp for uses and doses the FDA had specifically declined to approve.

The resolution totaled $762 million: a $136 million criminal fine, $14 million in forfeiture, and $612 million to settle False Claims Act suits. The civil allegations covered off-label promotion, kickbacks and false price reporting across several drugs.

It was not the end. In April 2013 Amgen paid another $24.9 million over alleged kickbacks to long-term-care pharmacies supplying Aranesp. State consumer settlements and a 2019 copay-foundation case followed.

A guilty plea is the heaviest sanction available against a company. Here it came with a misdemeanor charge, no individual prosecutions, and fresh allegations four months later. The first bill was $762 million. The pattern it was meant to end continued.

Sources

  1. justice.gov · justice.gov/archive/usao/nye/pr/2012/2012dec19.html
  2. projects.propublica.org · projects.propublica.org/docdollars/companies/amgen

Cite this report

The Precedent. "Amgen pleaded guilty over Aranesp and paid $762 million. Then it kept paying.." September 18, 2026. https://theprecedent.org/article/amgen-pleaded-guilty-over-aranesp-and-paid-762-million-then-it-kept-paying

Companies in this report